HU216313B - Eljárás asztma kezelésére alkalmas gyógyszerkészítmények előállítására - Google Patents

Eljárás asztma kezelésére alkalmas gyógyszerkészítmények előállítására Download PDF

Info

Publication number
HU216313B
HU216313B HU902883A HU288390A HU216313B HU 216313 B HU216313 B HU 216313B HU 902883 A HU902883 A HU 902883A HU 288390 A HU288390 A HU 288390A HU 216313 B HU216313 B HU 216313B
Authority
HU
Hungary
Prior art keywords
icam
family
priority
september
glycoproteins
Prior art date
Application number
HU902883A
Other languages
English (en)
Hungarian (hu)
Other versions
HUT65843A (en
HU902883D0 (en
Inventor
Robert H. Gundel
Robert Rothlein
Craig D. Wegner
Original Assignee
Boehringer Ingelheim Pharmaceuticals Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharmaceuticals Inc. filed Critical Boehringer Ingelheim Pharmaceuticals Inc.
Publication of HU902883D0 publication Critical patent/HU902883D0/hu
Publication of HUT65843A publication Critical patent/HUT65843A/hu
Publication of HU216313B publication Critical patent/HU216313B/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70525—ICAM molecules, e.g. CD50, CD54, CD102
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • C07K14/70553—Integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2821—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against ICAM molecules, e.g. CD50, CD54, CD102
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2845—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HU902883A 1989-03-09 1990-03-09 Eljárás asztma kezelésére alkalmas gyógyszerkészítmények előállítására HU216313B (hu)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US32101889A 1989-03-09 1989-03-09
US32123989A 1989-03-09 1989-03-09
US32123789A 1989-03-09 1989-03-09
US32448189A 1989-03-16 1989-03-16
US40140989A 1989-09-01 1989-09-01

Publications (3)

Publication Number Publication Date
HU902883D0 HU902883D0 (en) 1991-12-30
HUT65843A HUT65843A (en) 1994-07-28
HU216313B true HU216313B (hu) 1999-06-28

Family

ID=27541038

Family Applications (1)

Application Number Title Priority Date Filing Date
HU902883A HU216313B (hu) 1989-03-09 1990-03-09 Eljárás asztma kezelésére alkalmas gyógyszerkészítmények előállítására

Country Status (13)

Country Link
EP (1) EP0387701B1 (enExample)
JP (1) JP3119483B2 (enExample)
KR (1) KR0177519B1 (enExample)
AT (1) ATE79270T1 (enExample)
AU (1) AU638450B2 (enExample)
CA (1) CA2047721C (enExample)
DE (1) DE69000248T2 (enExample)
DK (1) DK0387701T3 (enExample)
ES (1) ES2035668T3 (enExample)
GR (1) GR3006073T3 (enExample)
HU (1) HU216313B (enExample)
NZ (1) NZ232868A (enExample)
WO (1) WO1990010453A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0362531B1 (en) 1988-09-01 1999-11-10 Bayer Corporation A human rhinovirus receptor protein that inhibits virus infectivity
US6143298A (en) * 1988-09-01 2000-11-07 Bayer Corporation Soluble truncated forms of ICAM-1
ZA896668B (en) * 1988-09-01 1990-06-27 Molecular Therapeutics Inc A human rhinovirus receptor protein that inhibits virus infectivity
US6514936B1 (en) 1988-09-01 2003-02-04 Bayer Corporation Antiviral methods using human rhinovirus receptor (ICAM-1)
US6051231A (en) * 1988-09-01 2000-04-18 Bayer Corporation Antiviral methods and prepations
US5776775A (en) * 1989-02-21 1998-07-07 Dana-Farber Cancer Institute Anti-LAM 1-3 antibody and hybridoma
ATE184049T1 (de) * 1990-07-20 1999-09-15 Bayer Ag Multimere formen des menschlichen rhinovirus- rezeptorproteins
US5686581A (en) * 1990-07-20 1997-11-11 Bayer Corporation Multimeric form of human rhinovirus receptor protein
US5686582A (en) * 1990-07-20 1997-11-11 Bayer Corporation Multimeric forms of human rhinovirus receptor protein
US6107461A (en) * 1990-07-20 2000-08-22 Bayer Corporation Multimeric forms of human rhinovirus receptor and fragments thereof, and method of use
AU8765391A (en) * 1990-10-03 1992-04-28 Boehringer Ingelheim Pharmaceuticals, Inc. Method for treating inflammation using anti-idiotypic antibodies
CA2056143A1 (en) * 1990-11-28 1992-05-29 Michael S. Diamond The mac-1 binding site of icam-1
ATE145827T1 (de) * 1991-04-03 1996-12-15 Boehringer Ingelheim Pharma Verfahren zur hemmung der sauerstofftoxizität in den lungen
GB9115364D0 (en) * 1991-07-16 1991-08-28 Wellcome Found Antibody
EP0551501B1 (en) * 1991-07-31 1998-11-18 Boehringer Ingelheim Pharmaceuticals Inc. Use of endothelial-leukocyte adhesion molecule-1 and antibodies thereto in the treatment of asthma
EP0610298A1 (en) * 1991-10-01 1994-08-17 The General Hospital Corporation Preventing allograft rejection with antibodies to adhesion molecules
US5871734A (en) * 1992-01-13 1999-02-16 Biogen, Inc. Treatment for asthma with VLA-4 blocking agents
US5708141A (en) * 1992-05-11 1998-01-13 Corvas International, Inc. Neutrophil inhibitors
CA2116109A1 (en) * 1992-06-22 1994-01-06 Jeffrey M. Greve Multimeric forms of human rhinovirus receptor protein
US6391452B1 (en) 1997-07-18 2002-05-21 Bayer Corporation Compositions for nasal drug delivery, methods of making same, and methods of removing residual solvent from pharmaceutical preparations
US20030035798A1 (en) 2000-08-16 2003-02-20 Fang Fang Humanized antibodies
JP2005522192A (ja) 2001-07-19 2005-07-28 パーラン セラピューティクス， インコーポレイテッド マルチマータンパク質およびマルチマータンパク質を作製および使用する方法
GB0525214D0 (en) 2005-12-12 2006-01-18 Bioinvent Int Ab Biological materials and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE128727T1 (de) * 1987-05-04 1995-10-15 Dana Farber Cancer Inst Inc Interzellulare adhäsions-moleküle und deren bindungsliganden.
ATE114972T1 (de) * 1987-11-02 1994-12-15 Baylor College Medicine Verwendung von icam-1 oder ihre funktionelle derivate zur behandlung unspezifischer entzündungen.
CA1341055C (en) * 1987-12-08 2000-07-18 Alan Mcclelland Transfectant cell lines which express the major human rhinovirus receptor

Also Published As

Publication number Publication date
CA2047721C (en) 2004-01-06
HUT65843A (en) 1994-07-28
ES2035668T3 (es) 1993-04-16
DK0387701T3 (da) 1992-12-07
EP0387701A1 (en) 1990-09-19
KR920700667A (ko) 1992-08-10
WO1990010453A1 (en) 1990-09-20
ATE79270T1 (de) 1992-08-15
GR3006073T3 (enExample) 1993-06-21
JP3119483B2 (ja) 2000-12-18
HU902883D0 (en) 1991-12-30
CA2047721A1 (en) 1990-09-10
KR0177519B1 (ko) 1999-03-20
DE69000248D1 (de) 1992-09-17
JPH04504127A (ja) 1992-07-23
DE69000248T2 (de) 1993-01-07
NZ232868A (en) 1995-05-26
AU5349990A (en) 1990-10-09
EP0387701B1 (en) 1992-08-12
AU638450B2 (en) 1993-07-01

Similar Documents

Publication Publication Date Title
US5730983A (en) Use of intercellular adhesion molecules, and their binding ligands in the treatment of asthma
EP0387701B1 (en) Use of intercellular adhesion molecules, and their binding ligands in the treatment of asthma
US6358510B1 (en) ICAM-1 derivatives with altered ability to bind LFA-1
EP0387668B1 (en) Intercellular adhesion molecule - 2 and its binding ligands
US5288854A (en) Functional derivatives of ICAM-1 which are substantially capable of binding to LFA-1 but are substantially incapable of binding to MAC-1
DE69033983T2 (de) Verwendung von funktionellen Derivaten des Interzellulär-Adhäsions-Moleküls ICAM-1 in einer Antivirus-Therapie
JP3288042B2 (ja) 細胞間接着分子−３およびその結合リガンド
CA1341185C (en) Intercellular adhesion molecules and their binding ligands
US5831036A (en) Soluble fragments of human intercellular adhesion molecule-1
EP3706799B1 (en) Peptide for preventing, modulating and/or reducing cardiovascular disease
WO1993006842A1 (en) Use of intercellular adhesion molecules, and their binding ligands in the treatment of asthma
US5565550A (en) Antibodies to ICAM-2, and fragments thereof
US5512660A (en) Purified ICAM-2 and fragment thereof
US6797270B1 (en) Functional derivatives of the intercellular adhesion molecule ICAM-1 in anti-viral therapy
US6511664B1 (en) Intercellular adhesion molecule—2 and its binding ligands
US7354588B1 (en) Functional derivatives of ICAM-1 with altered ability to bind LFA-1 or HRV
US6777191B1 (en) Use of functional derivatives of the intercellular adhesion molecule ICAM-1 in diagnosis of viral infection
DD297417A5 (de) Interzellulares adhaesionsmolekuel-2 und seine bindungsliganden
JPH06145199A (ja) Ｉｃａｍ−１のｍａｃ−１結合部位